Kernspintomographie zum Metastasen-Screening? Ein prospektiver Vergleich mit der Skelettszintigraphie

Theissen, P.; Smolarz, Kamilla; Scharl, A.; Groth, Anne Karoline; Scheidhauer, Klemens; Voth, E.; Schicha, H.

doi:10.1055/s-0038-1629807

Cited by 6 publications

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma

Janni

Gastroph

Hepp

et al. 2000

Cancer

View full text Add to dashboard Cite

BACKGROUND Using cytokeratin (CK) as a histogenetic marker of epithelial tumor cells in the bone marrow of patients with primary breast carcinoma, a subgroup of patients with decreased survival can be identified. This study was designed to evaluate the frequency and prognostic relevance of such cells in patients with recurrent breast carcinoma. METHODS Bone marrow aspirates from 65 patients were analyzed immunocytochemically for the presence of CK positive cells. A quantitative immunoassay with monoclonal anti‐CK antibody A45‐B/B3 was used and 2 × 106 bone marrow cells per patient were evaluated. For prognostic evaluation the authors calculated a cutoff value of micrometastatic tumor cells by analogy to classification and regression tree (CART) analysis. Patients were monitored prospectively for a median of 37 months (range, 11–63 months). RESULTS Bone marrow micrometastases were present in 5 of 32 patients (16%) with locoregional recurrence and in 24 of 33 patients (73%) with distant recurrence. The bone marrow status yielded no prognostic indication for patients with locoregional recurrence. In contrast, a cutoff value of 2.5 tumor cells per 1 million bone marrow cells analyzed (2.5 × 10−6 tumor cells) correlated with a significantly different prognosis for women with distant disease. Patients with metastatic disease and a micrometastatic tumor load of > 2.5 × 10−6 tumor cells survived for a mean of 6 months (95% confidence interval [95% CI], 2.0–9.1) compared with 17 months (95% CI, 11.6–22.0) for patients with ≤ 2.5 × 10−6 tumor cells (P < 0.0001). Multivariate analysis, allowing for hormone receptor status, disease free interval prior to recurrence, manifestation site of metastases, age, and micrometastases in bone marrow, revealed that bone marrow involvement was an independent risk factor, with a hazard ratio of 7.4 (95% CI, 1.6–13.3) for disease‐related death. CONCLUSIONS An increased number of micrometastases identified in the bone marrow of patients with metastatic breast carcinoma represents an independent prognostic factor that may influence future therapeutic strategies for patients with metastatic breast carcinoma. Cancer 2000;88:2252–9. © 2000 American Cancer Society.

show abstract